Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177008 · ClinicalTrials.gov registry record · Phase 4
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
A Phase 4 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT00177008 is a Phase 4 study that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 18 participants.
The verdict
NCT00177008, a Phase 4 study, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will determine the efficacy of a medication switch to Aripiprazole for the treatment of schizophrenia or schizoaffective disorder in patients with moderate to high symptoms of social anxiety. Specifically the study will test the possibility that a medication switch to Aripiprazole reduces symptoms of social anxiety in this patient population.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177008
The ClinicalTrials.gov registry entry for NCT00177008 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00177008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177008 about?
NCT00177008 is a clinical study titled "Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety". This study will determine the efficacy of a medication switch to Aripiprazole for the treatment of schizophrenia or schizoaffective disorder in patients with moderate to high symptoms of social anxiety. Specifically the study will test the possibility that a medication switch to Aripiprazole reduces...
What is the current status of trial NCT00177008?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2004-03. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00177008?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00177008?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.